Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

Cambridge, USA-based mRNA vaccines company Moderna today announced the expansion of its US manufacturing capabilities with ...

ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today ...

Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger ...

The importance of minority-interest remeasurement has expanded as joint venture and platform-licensing models become more common in biotech. For investors, such metrics provide an improved lens for ...

Novartis' two new sites in North Carolina fall under the Swiss pharma’s $23bn US manufacturing onshoring ploy.

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, ...

U.S. patent granted for CRISPR-Cas9 RNP platform technology in the world's largest biotech market - Next-generation platform that enhances editing efficiency and ...

A breakthrough in pregnancy research is changing our understanding of how gestational diabetes impacts mother and child.

Study Uncovers Molecular Disruptions in Placenta Caused by Gestational Diabetes A breakthrough in pregnancy research is ...